我要投票 三金SANJIN在口气清新剂行业中的票数:244
· 外 推 电 报 ·
2025-02-24 00:19:28 星期一

【三金SANJIN是哪个国家的品牌?】

三金SANJIN是什么牌子?「三金SANJIN」是 桂林三金药业股份有限公司 旗下著名品牌。该品牌发源于广西,由创始人邹节明在1994期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力三金SANJIN品牌出海!通过在本页面挂载三金SANJIN品牌的产品链接和联系邮箱,可以提高三金SANJIN产品曝光!跨境电商爆单神器,目前只要100元/年哦~

桂林三金药业股份有限公司是三金集团的核心企业,主营中成药、天然药物的研发和生产,是国内较早生产现代中药制剂的厂家之一,也是广西医药龙头企业。1985年以来,桂林三金坚持改革创新,依靠科技进步和科学管理,从一个名不见经传的中药作坊小厂蜕变成为全国知名的现代中药企业。

三金作为区内外知名的高新技术企业,建有国家认定的企业技术中心、博士后科研工作站及广西中药产业化工程院等创新平台。多年来,一直致力推进和实施中药产业现代化规划,积极培养、提高企业的自主创新能力。目前公司的特色中药新药均由企业技术中心主导研制。目前,三金拥有200多个注册品种和13个药品剂型,拥有桂林西瓜霜、西瓜霜润喉片、三金片、脑脉泰胶囊等自主开发的特色品种42种。经过多年努力,三金在咽喉、口腔用药和泌尿系统用药方面已形成较强的专业和市场优势,代表产品三金西瓜霜系列、三金片。“三金”牌产品已行销海内外,并享有良好声誉。

2009年7月,桂林三金以高成长、高效益的崭新面貌,成功进入资本市场,迎来企业高速发展的新阶段。近年来,为积极响应桂林市委、市政府“向西发展,再造一个新桂林”的号召,也为解决企业生产基地及仓储设施分散与企业快速发展之间的矛盾,三金启动了“三金现代中药产业化技术改造工程”的建设。目前,该项目一期已经正式投产并实现了主要生产线的整体搬迁。

面对未来,三金将秉承“创新推动医药进步”的企业使命和“敢为先”企业精神,实施以中药制药为主体,致力发展生物制药和大健康产业的”一体两翼”发展战略,视质量、信誉为企业第一生命,突破创新,不断增强三金的竞争实力,锐意进取,以发展报国、回报投资者,以打造中国知名医药制造集团为目标,推动中药产业现代化、国际化!


英文翻译:Guilin Sanjin Pharmaceutical Co., Ltd. is the core enterprise of Sanjin group, which is mainly engaged in the research and development and production of Chinese patent medicine and natural medicine. It is one of the earliest manufacturers of modern Chinese medicine preparations in China, and also the leading enterprise of Guangxi medicine. Since 1985, Guilin Sanjin has persisted in reform and innovation, relying on scientific and technological progress and scientific management, and has transformed from an unknown small traditional Chinese medicine workshop into a well-known modern Chinese medicine enterprise in China. As a well-known high-tech enterprise inside and outside the zone, Sanjin has established a national recognized enterprise technology center, postdoctoral research workstation, Guangxi Institute of traditional Chinese medicine industrialization and other innovation platforms. Over the years, we have been committed to promoting and implementing the modernization plan of traditional Chinese medicine industry, and actively cultivating and improving the independent innovation ability of enterprises. At present, the company's characteristic new Chinese medicine is mainly developed by the enterprise technology center. At present, Sanjin has more than 200 registered varieties and 13 pharmaceutical dosage forms, and 42 self-developed characteristic varieties such as Guilin Watermelon cream, watermelon cream throat moistening tablet, Sanjin tablet, Naomaitai Capsule, etc. After years of efforts, Sanjin has formed strong professional and market advantages in throat, oral medicine and urinary system medicine, representing Sanjin watermelon cream series and Sanjin tablets. "Three gold" brand products have been sold at home and abroad, and enjoy a good reputation. In July 2009, Guilin Sanjin successfully entered the capital market and ushered in a new stage of rapid development of enterprises with a new look of high growth and high efficiency. In recent years, in order to actively respond to the call of Guilin municipal Party committee and municipal government to "develop to the West and rebuild a new Guilin", and to solve the contradiction between the scattered production base and storage facilities of enterprises and the rapid development of enterprises, Sanjin has launched the construction of "Sanjin modern Chinese medicine industrialization technology transformation project". At present, the first phase of the project has been officially put into operation and the overall relocation of the main production lines has been realized. In the future, Sanjin will adhere to the enterprise mission of "innovation promotes pharmaceutical progress" and the enterprise spirit of "dare to be the first", implement the development strategy of "one body and two wings" with traditional Chinese medicine as the main body, devote to the development of biopharmaceutical and big health industry, regard quality and reputation as the life of the enterprise, break through innovation, continuously enhance the competitiveness of Sanjin, forge ahead, serve the country and return with development Newspaper investors, with the goal of building a well-known Chinese pharmaceutical manufacturing group, to promote the modernization and internationalization of traditional Chinese medicine industry!

本文链接: https://www.waitui.com/brand/7e6028fbc.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

深圳:近期将发布人形机器人专项政策 在全市科技重大专项中安排人工智能和机器人专项

深圳市政府新闻办2月23日召开“打造最好科技创新生态和人才发展环境”主题新闻发布会。市人工智能产业办主任林毅在会上表示,深圳在人工智能和机器人领域基础雄厚、未来可期。下一步,我们将在政策、场景、创新、机器人四个方面持续发力。此外,近期我们还将发布人形机器人专项政策,通过“揭榜挂帅”等方式,对开放应用场景、突破关键技术、构建专用数据集、提升规模化制造和应用能力等予以精准支持。同时,还将在全市科技重大专项中安排人工智能和机器人专项,鼓励产、学、研、用组成创新联合体进行协同攻关。(财联社)

20分钟前

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

20分钟前

2025年中央一号文件发布

36氪获悉,2025年中央一号文件2月23日发布,《中共中央 国务院关于进一步深化农村改革 扎实推进乡村全面振兴的意见》提出,以改革开放和科技创新为动力,巩固和完善农村基本经营制度,深入学习运用“千万工程”经验,确保国家粮食安全,确保不发生规模性返贫致贫,提升乡村产业发展水平、乡村建设水平、乡村治理水平,千方百计推动农业增效益、农村增活力、农民增收入,为推进中国式现代化提供基础支撑,这是党的十八大以来第13个指导“三农”工作的中央一号文件。

20分钟前

海天味业:公司发行H股备案申请材料获中国证监会接收

36氪获悉,海天味业公告称,公司已于2025年1月13日向香港联交所递交了发行H股股票并在香港联交所主板挂牌上市的申请。公司已向中国证监会报送了关于公司本次发行的备案申请材料并于近日获中国证监会接收。该事项仍存在不确定性,公司将根据进展情况及时履行信息披露义务。

20分钟前

山河药辅:股东复星医药拟减持不超过3%公司股份

36氪获悉,山河药辅发布公告,股东上海复星医药产业发展有限公司因经营需要,计划以集中竞价和大宗交易方式合计减持公司股份不超过697.8万股,即不超过公司总股本的3%。

20分钟前

本页详细列出关于屈臣氏Watsons的品牌信息,含品牌所属公司介绍,屈臣氏Watsons所处行业的品牌地位及优势。
咨询